Published in J Neurovirol on July 25, 2014
International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29
Dynamic modulation of HSV chromatin drives initiation of infection and provides targets for epigenetic therapies. Virology (2015) 0.87
CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies. Mol Psychiatry (2015) 0.85
Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol Sin (2015) 0.80
Nicotine mediates expression of genes related to antioxidant capacity and oxidative stress response in HIV-1 transgenic rat brain. J Neurovirol (2015) 0.77
Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. J Leukoc Biol (2015) 0.76
Neuronal Cell Death and Degeneration through Increased Nitroxidative Stress and Tau Phosphorylation in HIV-1 Transgenic Rats. PLoS One (2017) 0.75
A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice. AIDS Res Treat (2017) 0.75
Targeting the Brain Reservoirs: Toward an HIV Cure. Front Immunol (2016) 0.75
Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. PLoS Pathog (2017) 0.75
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell (1987) 12.30
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science (1986) 8.01
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol (1993) 6.79
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature (1989) 5.76
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
The Sp-family of transcription factors. Gene (1999) 5.05
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 4.55
NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell (2001) 4.55
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J (1993) 3.74
Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science (1995) 3.50
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
CNS immune privilege: hiding in plain sight. Immunol Rev (2006) 3.13
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res (1992) 2.89
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science (1990) 2.74
A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. Mol Cell (1999) 2.73
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol (1999) 2.53
Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol (2003) 2.50
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
HIV: Shock and kill. Nature (2012) 2.45
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem (2010) 2.23
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Interaction and functional collaboration of p300 and C/EBPbeta. Mol Cell Biol (1997) 2.12
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol (1994) 2.07
Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol (2002) 2.03
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.00
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet (2006) 1.91
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology (1994) 1.86
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol (1995) 1.74
Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res (1994) 1.65
C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol (1995) 1.64
Immune surveillance in the central nervous system. Nat Neurosci (2012) 1.63
Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem (1995) 1.58
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res (2003) 1.47
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci U S A (1998) 1.35
Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol Chem (1995) 1.34
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem (1998) 1.22
Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. J Infect Dis (2006) 1.19
Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem (2002) 1.19
Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. AIDS (1995) 1.18
Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response. J Virol (2005) 1.17
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.15
Astrocytes. Sci Am (1989) 1.13
Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors. Virology (1999) 1.09
Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS (2013) 1.07
HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol (2009) 1.04
The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett (2011) 1.01
The search for an HIV cure: tackling latent infection. Lancet Infect Dis (2013) 0.98
Restricted expression of HIV1 in human astrocytes: molecular basis for viral persistence in the CNS. Res Virol (1995) 0.95
Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol (2004) 0.94
Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. J Virol (2000) 0.92
HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. J Neurovirol (2001) 0.91
Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol (2003) 0.90
HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One (2014) 0.90
In vitro chromatin assembly of the HIV-1 promoter. ATP-dependent polar repositioning of nucleosomes by Sp1 and NFkappaB. J Biol Chem (1997) 0.89
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2011) 0.89
Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol (2004) 0.88
High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol (2004) 0.87
NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. J Virol (2001) 0.87
High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia. AIDS Res Hum Retroviruses (2007) 0.85
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One (2013) 0.85
Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults? HIV Med (2011) 0.85
NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors. Mini Rev Med Chem (2009) 0.83
Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses (2012) 0.83
Is specific HIV eradication from the brain possible or needed? Expert Opin Biol Ther (2013) 0.83
Update on HIV dementia and HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep (2014) 0.82
CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection. Future Microbiol (2009) 0.82
NF-kappa B site-mediated negative regulation of the HIV-1 promoter by CCAAT/enhancer binding proteins in brain-derived cells. J Mol Neurosci (1995) 0.80
Localization of HIV-1 DNA and tumor necrosis factor-alpha mRNA in human brain using polymerase chain reaction in situ hybridization and immunocytochemistry. Methods Mol Biol (2000) 0.76
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis (2010) 1.52
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Mechanisms of HIV-1 neurotropism. Curr HIV Res (2006) 1.33
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol (2006) 1.19
Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response. J Virol (2005) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One (2010) 1.12
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology (2008) 1.10
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis (2002) 1.07
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol (2004) 1.02
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology (2011) 1.00
Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses (2008) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00
Novel pathway of human immunodeficiency virus type 1 uptake and release in astrocytes. Virology (2006) 0.99
Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol (2005) 0.98
Vaccine presentations and delivery technologies--what does the future hold? Expert Rev Vaccines (2005) 0.95
Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source. Virol J (2007) 0.95
CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol (2010) 0.94
CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology (2013) 0.94
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology (2012) 0.94
Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol (2010) 0.94
Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J Virol (2011) 0.93
Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS (2014) 0.93
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. PLoS One (2013) 0.92
Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus. Retrovirology (2007) 0.92
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol (2012) 0.92
Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses (2006) 0.91
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res (2011) 0.91
CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Virology (2011) 0.91
Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues. Retrovirology (2011) 0.90
Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol (2002) 0.89
A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. J Virol Methods (2010) 0.89
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology (2013) 0.88
Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology (2008) 0.86
Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology (2013) 0.86
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology (2013) 0.86
Appetising solutions: an edible vaccine for measles. Med J Aust (2002) 0.86
Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology (2009) 0.86
Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology (2013) 0.85
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One (2013) 0.85
CXCR4 or CCR5 tropism of human immunodeficiency virus type 1 isolates does not determine the immunological milieu in patients responding to antiretroviral therapy. Viral Immunol (2006) 0.85
Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies. Retrovirology (2014) 0.84
Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int J Parasitol (2007) 0.83
Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. J Acquir Immune Defic Syndr (2005) 0.83
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One (2011) 0.83
Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses (2012) 0.83
In vivo replication kinetics of a nef-deleted strain of HIV-1. AIDS (2005) 0.83
High viral fitness during acute HIV-1 infection. PLoS One (2010) 0.82
A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. Nucleic Acids Res (2012) 0.81
Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients. Mitochondrion (2010) 0.81
Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology (2010) 0.79
Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnol J (2009) 0.79
HIV-1 entry inhibitors: classes, applications and factors affecting potency. Curr HIV Res (2006) 0.79
Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry. ACS Chem Biol (2014) 0.78
Is there a role for plant-made vaccines in the prevention of HIV/AIDS? Immunol Cell Biol (2005) 0.78
Pathogenesis and diagnosis of viral infections of the nervous system. Neurol Clin (2008) 0.76
Measuring and monitoring apoptosis and drug toxicity in HIV patients by ligation-mediated polymerase chain reaction. J Cell Mol Med (2008) 0.76
Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12. Virology (2012) 0.75
Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders. Clin Immunol (2010) 0.75